Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis
Open Access
- 9 June 2010
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 67
Abstract
Background: Previous meta-analysis suggested that transdermal fentanyl was not inferior to sustained-release oral morphine in treating moderate-severe cancer pain with less adverse effects. Now, we updated the data and performed a systematic review. Methods: Updated cohort studies on transdermal fentanyl and oral morphine in the treatment of cancer pain were searched in electronic databases including CBMdisc, CNKI, VIP, Medline, EMBASE and Cochrane Library. Primary end points assessed by meta-analysis were remission rate of pain and incidence of adverse effects. Quality of life was assessed by systematic review, which was the second end point. Results: 32 cohort studies, which included 2651 patients, were included in present study. The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23]. Compared with oral morphine group, there were less adverse effects in terms of constipation [RR = 0.35, 95% CI (0.27, 0.45), P < 0.00001], nausea/vomiting [RR = 0.57, 95% CI (0.49, 0.67), P < 0.00001], and vertigo/somnolence [RR = 0.59, 95% CI (0.51, 0.68), P < 0.00001] in transdermal fentanyl group. Six of selected trials supported either transdermal fentanyl or sustained-release oral morphine improved QOL of cancer patients and one of them showed more patients got better QOL after sustained-release oral morphine transferred to transdermal fentanyl. Conclusions: Our study showed again that both transdermal fentanyl and oral morphine had the same efficacy in the treatment of moderate-severe cancer pain in Chinese population, but the former might have less adverse effects and better quality of life.Keywords
This publication has 12 references indexed in Scilit:
- Transdermal Fentanyl as A Front-Line Approach to Moderate-Severe Pain: A meta-analysis of Randomized Clinical TrialsJournal of Palliative Care, 2009
- Adverse Effects of Transdermal Opiates Treating Moderate-Severe Cancer Pain in Comparison to Long-Acting Morphine: A Meta-Analysis and Systematic Review of the LiteratureJournal of Palliative Medicine, 2008
- Amateur boxing and risk of chronic traumatic brain injury: systematic review of observational studiesBMJ, 2007
- Pain Management: A Fundamental Human RightAnesthesia & Analgesia, 2007
- [Transdermal fentanyl for the management of cancer pain: a survey of 4492 patients].2005
- Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer painCurrent Medical Research and Opinion, 2004
- Incidence of Constipation Associated with Long-acting Opioid Therapy: A Comparative StudySouthern Medical Journal, 2004
- Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis BJournal of Chinese Integrative Medicine, 2003
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000
- Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of lifeJournal of Pain and Symptom Management, 1997